Neuroinflammation as a possible link between cannabinoids and addiction
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Objective: Substance dependence disorder is a chronically relapsing condition characterised by neurobiological changes leading to loss of control in restricting a substance intake, compulsion and withdrawal syndrome. In the past few years, (endo)cannabinoids have been raised as a possible target in the aetiology of drug addiction. On the other hand, although the exact mechanisms of the genesis of addiction remain poorly understood, it is possible that neuroinflammation might also play a role in the pathophysiology of this condition. Studies demonstrated that (endo)cannabinoids act as immunomodulators by inhibiting cytokines production and microglial cell activation. Thus, in the present review, we explore the possible role of neuroinflammation on the therapeutic effects of cannabinoids on drug addiction. Methods: We conducted an evidence-based review of the literature in order to assess the role of cannabinoids on the neuroinflammatory hypothesis of addiction (terms: addiction, cannabinoids and inflammation). We searched PubMed and BioMedCentral databases up to April 2014 with no date restrictions. Results: In all, 165 eligible articles were included in the present review. Existing evidence suggests that disruption in cannabinoid signalling during the drug addiction process leads to microglial activation and neuroinflammation. Conclusion: The literature showed that inflammation and changes in endocannabinod signalling occur in drug abuse; however, it remains uncertain whether these changes are causally or coincidentally associated with addiction. Additional studies, therefore, are needed to elucidate the contribution of neuroinflammation on the behavioural and neuroprotective effects of cannabinoids on drug addiction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090 · cited 1×
“The activity of these ligands is terminated by the enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively (18).”
BackgroundCombs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Eljaschewitsch, E., Witting, A., Mawrin, C., Lee, T., Schmidt, P. M., Wolf, S., Hoertnagl, H., Raine, C. S., Schneider-Stock, R., Nitsch, R., et al. (2006) · Neuron · doi:10.1016/j.neuron.2005.11.027 · Cited by 445
Brain cannabinoid CB2 receptors modulate cocaine's actions in mice
Xi, Z.-X., Peng, X.-Q., Li, X., Song, R., Zhang, H.-Y., Liu, Q.-R., Yang, H.-J., Bi, G.-H., Li, J., & Gardner, E. L. (2011) · Nature Neuroscience · doi:10.1038/nn.2874 · Cited by 397 · cited 1×
“One possibility to explain this effect is that activation of CB2 receptors on astrocytes or microglia could alter the production of proinflammatory mediators, which would inhibit DA release from the nucleus accumbens (164).”
BackgroundCohen, C., Perrault, G., Voltz, C., Steinberg, R., & Soubrié, P. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200209000-00018 · Cited by 396 · cited 1×
“Cross-talk between nicotine addiction and the endocannabinoid system was confirmed in experiments that showed that treatment with a CB1 antagonist reduced nicotine self-administration and place preference in rodents that was associated with a decrease in DA release in the nucleus accumbens (88,89).”
BackgroundFunctional interaction between opioid and cannabinoid receptors in drug self-administration.
Navarro, M., Carrera, M. R. A., Fratta, W., Valverde, O., Cossu, G., Fattore, L., Chowen, J. A., Gómez, R., del Arco, I., Villanúa, M. A., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-14-05344.2001 · Cited by 378 · cited 1×
“Consistent with these findings, the CB1 receptor antagonist, rimonabant, reduces the reinforcing effects of self-administered heroin and inhibits reinstatement to this opiate (79,80).”
ResultPsychostimulant abuse and neuroinflammation: emerging evidence of their interconnection.
Clark, K. H., Wiley, C. A., & Bradberry, C. W. (2013) · Neurotoxicity Research · doi:10.1007/s12640-012-9334-7 · Cited by 194
Role of Tumor Necrosis Factor-α in Methamphetamine-Induced Drug Dependence and Neurotoxicity
Nakajima, A., Yamada, K., Nagai, T., Uchiyama, T., Miyamoto, Y., Mamiya, T., He, J., Nitta, A., Mizuno, M., Tran, M. H., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4847-03.2004 · Cited by 176
Regulation of the Human Serotonin Transporter by Interleukin-1β
Ramamoorthy, S., Ramamoorthy, J. D., Prasad, P. D., Bhat, G. K., Mahesh, V. B., Leibach, F. H., & Ganapathy, V. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2659 · Cited by 156
Anandamide Inhibits Nuclear Factor-κB Activation through a Cannabinoid Receptor-Independent Pathway
Sancho, R., Calzado, M. A., Di Marzo, V., Appendino, G., & Muñoz, E. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.2.429 · Cited by 120
Disordered Sleep, Nocturnal Cytokines, and Immunity in Alcoholics
Redwine, L., Dang, J., Hall, M., & Irwin, M. (2003) · Psychosomatic Medicine · doi:10.1097/01.psy.0000038943.33335.d2 · Cited by 109
Sadasivan, S., Pond, B. B., Pani, A. K., Qu, C., Jiao, Y., & Smeyne, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033693 · Cited by 102
The unfolding web of innate immune dysregulation in alcoholic liver injury
Szabo, G., Mandrekar, P., Petrasek, J., & Catalano, D. (2011) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01398.x · Cited by 82
Merighi, S., Gessi, S., Varani, K., Fazzi, D., Mirandola, P., & Borea, P. A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01948.x · Cited by 79 · cited 1×
“CB2 receptor stimulation reduced morphineinduced production of inflammatory mediators from activated microglia (163).”
Background
Cited by
Cannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446
Self-citationPathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric Disorders
Hong, H., Kim, B. S., & Im, H.-I. (2016) · International Neurourology Journal · doi:10.5213/inj.1632604.302 · Cited by 258
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx073 · Cited by 226
“CBD acts like a PPARγ agonist through receptor-dependent mechanisms [23,234,235].”
BackgroundRole of Glial Cells in Neuronal Function, Mood Disorders, and Drug Addiction
Tizabi, Y., Getachew, B., Hauser, S. R., Tsytsarev, V., Manhães, A. C., & da Silva, V. D. A. (2024) · Brain Sciences · doi:10.3390/brainsci14060558 · Cited by 27
Targeting neuroinflammation: The therapeutic potential of ω-3 PUFAs in substance abuse
Peng, S., Peng, Z., Qin, M., Huang, L., Zhao, B., Wei, L., Ning, J., Tuo, Q.-H., Yuan, T.-F., Shi, Z., et al. (2021) · Nutrition · doi:10.1016/j.nut.2020.111058 · Cited by 18
Metadata
- Authors
- Rodrigues, L. C. M., Gobira, P. H., de Oliveira, A. C., Pelição, R., Teixeira, A. L., Moreira, F. A., & Campos, A. C.
- Venue
- Acta Neuropsychiatrica
- Publisher
- Cambridge University Press (CUP)
- Published
- 2013-10-02
- Volume
- 26
- Issue
- 6
- Pages
- 334-346
- ISSN
- 0924-2708 (ISSN-L)
- 1601-5215
- OpenAlex
- W2136749578
- Cited by
- 29
- References
- 14
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.